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DNA copy number changes were investigated in 51 (19 uterine and 32 nonuterine) primary leiomyosarcomas by 
comparative genomic hybridization. The aim was to evaluate whether true biological differences exist between 
uterine and nonuterine leiomyosarcoma and whether changes revealed by comparative genomic hybridization 
have prognostic value. Genomic imbalances were found in 48 (94%) cases. The most frequent DNA copy 
number changes were losses in 10q (35%), 13q (57%), and 16q (41%), gains in 1q (41%), and gains and high-level 
amplifications in 17p (39%). Gains were nearly as frequent as losses in both uterine and nonuterine 
leiomyosarcoma. Correlation-based tree modeling revealed two clusters that segregated significantly a group 
of uterine (gains at 1q11–q24) and a group of nonuterine (losses at 13q14–q34, 16q11.1–q24, and 10q21–q26) 
cases. The nonuterine cluster was associated with subcutaneous origin and a trend toward increased 
metastasis-free survival. Further explorative analyses identified aberrations associated with shorter metastasis­
free survival time, including losses at 2q32.1–q37 and gains at 8q24.1–q24.3, whereas the cases with losses at 
6cen-p25 showed longer metastasis-free survival time.
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Leiomyosarcomas are malignant mesenchymal tu­
mors composed of cells with phenotypic features of 
smooth muscle differentiation.1–3 These tumors 
occur in a wide range of anatomic body sites. 
Although the histological appearance of all leio­
myosarcomas, regardless of the anatomic site, is 
similar, they are usually divided into site-related 
groups due to clinical and biological differences.1–3 
Leiomyosarcoma is one of the most common 
sarcomas of the uterus4,5 but less frequent in 
external soft tissues. Subcutaneous and deep-seated 
leiomyosarcomas of soft tissue occur in approxi­
mately equal proportions, and they are supposed to
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originate from small to medium-sized veins.6–10 
Cutaneous leiomyosarcomas constitute an entity 
that arises from dermis, most probably from arrec­
tores pilorum muscles, and shows an indolent 
course of disease in contrast to leiomyosarcomas of 
other locations.11,12
Cytogenetic analyses of more than 100 leiomyo­
sarcoma cases have been reported.13,14 Standard 
karyotyping and fluorescent in situ hybridization 
have not revealed any single specific aberration 
common to all or most leiomyosarcomas, but many 
nonrandom structural aberrations and numerical 
changes have been detected. Cytogenetic signs of 
gene amplification have also been seen in leiomyo­
sarcoma. Most reported karyotypes are complex, 
contain a high number of chromosomal changes, 
and show marked heterogeneity within this group of 
sarcomas.14–19 Comparative genomic hybridization 
(CGH) studies have also shown multiple and 
complex changes, suggesting a genetically advanced
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disease. So far, CGH has been used to identify gains 
and losses of DNA copy number changes in less than 
200 cases of leiomyosarcoma. Extensive genetic 
imbalances have been detected in nearly all 
cases.20–28
Surgery is the main treatment modality for 
leiomyosarcoma irrespective of localization. Pre- or 
postoperative radiation therapy is used in high­
grade tumors and in cases where sufficient surgical 
margins cannot be obtained. In uterine leiomyosar­
coma, the primary therapy is extrafascial hysterect­
omy and bilateral salphingo-oophorectomy with or 
without pelvic lymphadenectomy.29 Radiation ther­
apy or chemotherapy is used as the only treatment 
modality when the tumor is thought to be inoperable 
or widespread.5,30 The use of cytotoxic drugs as 
adjuvant therapy has been more common in uterine 
leiomyosarcoma than in external soft tissue leio­
myosarcoma, even when no significant survival 
benefit has been derived.5,29,31 It is uncertain 
whether this difference in treatment tradition 
reflects a true difference in biology.
In order to evaluate whether true biological 
differences exist between uterine and non-uterine 
leiomyosarcoma, we undertook to study 51 primary 
leiomyosarcomas, which to our knowledge 
represent the largest series of leiomyosarcoma 
cases analyzed by the CGH technique so far. The 
aims of this study were to compare the genetic 
changes in these two leiomyosarcoma groups 
using CGH to obtain a genome-wide pattern 
of chromosomal gains, losses, and high-level ampli­
fications of small chromosomal areas, and to further 
evaluate their possible prognostic and/or diagnostic 
significance.
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excluded. No universally agreed grading system for 
uterine leiomyosarcoma exists. However, these 
tumors were categorized to ‘low grade' or ‘high 
grade' based on the degree of cellular atypia, amount 
of tumor necrosis and number of mitotic figures. A 
four-grade system based on similar parameters was 
applied to non-uterine tumors (I–II, low grade; III– 
IV, high grade). The depth of the superficial 
(cutaneous vs subcutaneous) non-uterine tumors 
was specified, and possible connection to a blood 
vessel was determined microscopically and from the 
primary pathologist's reports.
Of the 51 patients, 32 (63%) (14 males and 18 
females) had non-uterine leiomyosarcoma and 19 
(37%) uterine leiomyosarcoma. The non-uterine 
group consisted of nine cutaneous, 11 subcutaneous 
and 12 deep-seated tumors. The whole study series 
comprised 19 (37%) low-grade and 32 (63%) high­
grade tumors. The median age of the patients at 
diagnosis was 59 years (range, 20–91). Tumor sizes 
varied from 0.7 to 420.0 cm, with a median tumor 
size of 5.0 cm (non-uterine 3.5 cm and uterine 
7.0 cm). None of the patients had received chemo- 
and/or radiotherapy before surgery. The median 
follow-up time for all surviving patients was 
73 months, ranging from 9 months to 212 months. 
Metastatic dissemination was observed in five 
(10%) of the patients at the presentation, and 
16 patients developed a metastatic course of 
disease during the follow-up; altogether 41% of 
the patients progressed to metastasis. Local 
recurrence was recorded in 10 (20%) patients. 
Clinical characteristics of the patients are presented 
in Table 1.
Materials and methods
Tumor Specimens
The material consisted of 51 primary leiomyosar­
coma samples obtained from 51 Finnish patients 
treated at the Helsinki University Central Hospital, 
Helsinki between 1981 and 2003. The primary 
tumors were situated on the extremities, trunk wall, 
in the superficial head and neck region, and in the 
uterus. Complete clinical and follow-up data were 
available. Surgical and adjuvant treatments, and 
development of local and distant recurrences were 
documented. Two experienced sarcoma pathologists 
(TB, RB) performed the histopathological review to 
confirm the diagnosis and re-evaluate the tumor 
grading. All cases were histologically clear leiomyo­
sarcomas showing smooth muscle differentiation. 
Immunohistochemically, the tumors were positive 
for a-smooth muscle actin and showed at least focal 
positivity for desmin. The uterine leiomyosarcoma 
diagnosis was based on the morphological criteria 
by Bell et al.32 No uterine epitheloid or myxoid 
leiomyosarcomas were included in the study and 
also tumors of uncertain malignant potential were
Comparative Genomic Hybridization
DNA was extracted from paraffin-embedded tissue 
sections from all 51 tumor samples following the 
procedure reported by Isola et al.33 CGH was 
performed using direct fluorochrome-conjugated 
DNA for all samples as described elsewhere.34,35 
Briefly, tumor and reference DNA (genomic DNA 
from peripheral blood leukocytes from normal 
donors) were labeled with fluorescein-iso-thiocya- 
nate (FITC)-conjugated dCTP and dUTP (Dupont, 
Boston, MA, USA), and Texas red-conjugated dCTP 
and dUTP (Dupont) by nick translation, respec­
tively, to obtain fragments ranging from 600 to 
2000 bp, as published previously.35,36 The hybridiza­
tion mixture consisted of 400 ng tumor DNA, 400 ng 
reference DNA, and 10 mg unlabeled human Cot-1 
DNA (Gibco/BRL, Life Technologies, Gaithersburg, 
MD, USA) dissolved in 10 ml hybridization buffer 
(50% formamide, 10% dextran sulfate, 2 ^ SSC). 
The hybridization mixture was denatured at 751C for 
5 min and hybridized to a slide with normal 
metaphase spreads denatured in 70% formamide/ 
2 ^ SSC (pH 7) at 68 1 C for 2 min. Hybridization was 
carried out at 371C for 48 h. Then the slides were
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Table 1 Clinical characteristics of the 51 primary leiomyosarcoma patients studied
Sample number Sex/Age (years) 
at diagnosis
Tumor site Tumor size 
(cm)
Tumor grade Local Recurrence 
(months)
Metastasis
(months)
Follow-up
(months)
Last follow-up status Cause of death
1 M/20 Shoulder, cutaneous 0.8 I 104.6 NED
2 M/57 Upper trunk, cutaneous 2.0 I 97.1 NED
3 M/36 Head and neck, cutaneous 1.2 II 9.9 182.5 NED
4 F/37 Lower leg, subcutaneousa 0.7 II 78.8 103.7 204.3 DEA FT
5 F/64 Foot, subcutaneousa,b,c 3.0 II 77.1 NED
6 F/44 Lower leg, subcutaneousc 6.0 II 138.4 NED
7 M/78 Upper trunk, cutaneousc 0.7 II 29.9 DEA WHT
8 F/25 Upper arm, cutaneousc 1.0 II 182.8 NED
9 M/65 Upper trunk, cutaneous 0.9 II 30.8 NED
10 M/55 Upper trunk, cutaneous 1.8 II 137.7 NED
11 F/85 Head and neck, cutaneousc 1.3 III 42.0 DEA UNK
12 M/46 Thigh, cutaneousc 2.3 III 49.3 NED
13 M/55 Thigh, deepb,c 17.0 III 42.1 20.8 70.4 DEA FT
14 F/59 Upper trunk, subcutaneousc 3.0 III 193.4 NED
15 M/49 Groin, subcutaneousa,b,c 3.5 III 1.4 68.7 NED
16 F/62 Thigh, subcutaneousa,c 3.0 III 159.5 NED
17 F/80 Hand, subcutaneousa,b,c 2.0 III 72.5 DEA WHT
18 M/61 Thigh, deepc 8.0 III 40.4 211.9 NED
19 M/56 Upper trunk, deepb,c 3.5 III 64.8 DEA WHT
20 F/91 Thigh, subcutaneous 13.0 IV 4.1 8.0 DEA FT
21 M/79 Thigh, deepb,c 10.5 IV 28.7 22.0 28.7 DEA FT
22 M/71 Gluteal, subcutaneousc 8.0 IV 130.9 DEA WHT
23 F/75 Thigh, deepc 11.0 IV 6.9 7.2 DEA FT
24 F/55 Thigh, subcutaneousa,c 2.0 IV 78.9 135.2 DEA FT
25 F/74 Lower leg, subcutaneousa,d 7.0 IV 0.0 31.4 DEA FT
26 F/70 Thigh, deepa,b,c 10.0 IV 24.4 55.9 PER
27 F/77 Upper trunk, deepa,b,c 6.0 IV 6.9 6.9 7.6 DEA FT
28 M/35 Lower leg, deepd 10.0 IV 0.0 11.3 DEA FT
29 F/58 Knee, deepa,b,c,d 5.5 IV 0.0 59.7 DEA FT
30 F/60 Lower leg, deepb,c 17.0 IV 10.4 11.1 70.2 DEA FT
31 F/55 Thigh, deepb 10.0 IV 174.8 NED
32 F/84 Lower leg, deepb,c 4.0 IV 6.8 10.9 DEA FT
33 F/64 Uterus 10.0 Low 16.4 NED
34 F/75 Uterus 7.0 Low 12.2 NED
35 F/42 Uterusd 5.0 Low 27.0 86.0 NED
36 F/40 Uterus 5.0 Low 56.9 NED
37 F/48 Uterusb NA Low 7.0 9.0 DEA FT
38 F/49 Uterusd 6.0 Low 28.3 NED
39 F/34 Uterusd 4.0 Low 54.2 NED
40 F/69 Uterus (1600 g)e NA Low 25.7 DEA WHT
41 F/69 Uterusd 410.0 Low 0.0 35.9 DEA FT
42 F/58 Uterusd 4.0 High 26.6 NED
43 F/71 Uterusd (2200g)e 420.0 High 3.6 6.0 DEA FT
44 F/70 Uterusd (500 g)e NA High 8.0 81.6 DEA FT
45 F/64 Uterus 5.0 High 2.7 0.0 4.7 DEA FT
46 F/38 Uterusd 4.0 High 41.6 NED
47 F/64 Uterusb 8.0 High 24.6 64.9 DEA FT
48 F/69 Uterus (500 g)e NA High 121.7 DEA UNK
49 F/38 Uterusd 420.0 High 9.3f NED
50 F/53 Uterusd 10.0 High 21.7 DEA FT
51 F/81 Uterus 14.0 High 2.4 3.6 DEA FT
M, male; F, female; NA, not available; NED, no evidence of disease; DEA, dead; PER, persistent disease; FT, from tumor; WHT, without tumor; UNK, unknown. 
aVascular connection.
bPost operative radiotherapy. 
cAdequate local treatment.
dPost operative chemotherapy. 
eWeight of the organ at surgery.
fNo further follow-up data available.
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washed three times in 50% formamide/2 ^ SSC (pH 
7), twice in 2 ^ SSC, and once in 0.1 ^ SSC at 451C, 
followed by 2 ^ SSC, 0.1 M NaH2PO4—0.1 M Na2H- 
PO4—0.1% Nonidet P-40 (pH 8), and distilled water 
at room temperature for 10 min each. After air­
drying, the slides were counterstained with 40 ,6- 
diamidino-2-phenyl-indole-dihydrochloride (DAPI) 
(Sigma Chemical Co., St Louis, MO, USA) and 
mounted using an antifading medium (Vecta- 
shields, Vector Laboratories, Burlingame, CA, USA).
Digital Image Analysis
The hybridization was analyzed using an Olympus 
fluorescence microscope and the ISIS digital image 
analysis system (MetaSystems GmbH, Altlussheim, 
Germany), based on an integrated high-sensitivity 
monochrome charge-coupled device (CCD) camera 
and automated CGH analysis software. Three-color 
images (green for tumor DNA, red for reference 
DNA, and blue for counterstaining) were acquired 
from 12 metaphases per sample. The chromosomal 
regions were interpreted as over-represented when 
the green-to-red ratio exceeded 1.17 (gains) or 1.5 
(high-level amplifications), and as under-repre­
sented (losses) when the ratio was less than 
0.85. In each CGH experiment, a negative (periph­
eral blood DNA from normal donor) and 
positive (tumor DNA with known copy number 
changes) control were included and run 
simultaneously with the tumor samples. Telomeric 
and heterochromatinic regions were excluded 
from the analysis when they appeared as the 
sole aberration present in the sample, as these 
regions cannot be evaluated reliably by CGH.36,37 
All results were confirmed using a 99% confidence 
interval with a 1% error probability. Briefly, 
intraexperimental s.d. for all positions in the CGH 
ratio profiles were calculated from the variation of 
the ratio values of all homologous chromosomes 
within the experiment. Confidence intervals for the 
ratio profiles were then computed by combining 
them with an empirical interexperimental s.d. and 
by estimating the error probability based on the 
t-distribution.
Determination of Minimal Common Chromosomal 
Regions
CGH analyzes at a resolution down to the sub-band 
level of the chromosomes. CGH data were displayed 
on chromosome ideograms, where losses and gains 
of chromosome regions are presented as lines on the 
left or the right side of the ideogram, respectively. 
The minimal common regions of DNA copy number 
changes in the whole series were determined 
visually from the ideogram (supplementary data at 
www.helsinki.fi/cmg/cgh_data). The ideograms in 
Figures 1 and 2 show the difference between the 
uterine and non-uterine cases.
Statistical Analysis
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For both univariate and higher order statistical 
modeling of aberration patterns, a data set was 
constructed to reflect the presence or absence of 
aberrations in each individual case. Aberrations 
with no or limited information were excluded by 
requiring at least 10.0% of cases to share any 
particular aberration. Owing to their low overall 
occurrence, even single cases with high-level am­
plifications were included in the data set. The data 
was coded into binary variables, whereby 0 (zero) 
represented the absence and 1 (one) the presence of 
an aberration.
To assess the association between each individual 
chromosomal aberration and relevant clinical para­
meters, including tumor subtype (uterine vs non­
uterine), localization (cutaneous, subcutaneous, 
deep-seated or uterine), histologic grade (low-grade 
vs high-grade), and metastasis, a ‘prediction score' 
was calculated according to Golub et al.38 The score 
reflects the degree of correlation between the 
observed aberration pattern for all cases with an 
idealized pattern that perfectly discriminates be­
tween the categories of the clinical parameter being 
analyzed. In total, 173 scores were calculated and 
ranked in descending order, effectively placing 
aberrations with high discriminatory strength to 
the top of the list. A w2 test was subsequently run on 
the aberrations that generated the top 10 ranking 
scores to evaluate whether the proportion of cases 
with and without a particular aberration was 
statistically significantly different among the cate­
gories of the clinical parameter in question. Meta­
static status was further explored taking the time 
variable into account using the log-rank test to 
assess the differences in metastasis-free survival 
rates, calculated using the Kaplan–Meier method, 
between cases with and without a particular aberra­
tion. To reduce the likelihood of false positive 
results that may occur as a consequence of perform­
ing multiple individual univariate statistical tests, a 
conservative approach was adopted in interpreting 
the results. As chromosomal aberrations cannot be 
considered independent events, especially when 
these occur in adjacent loci, the Bonferroni type of 
correction was deemed inappropriate and an alter­
native strategy was devised. Only the results with 
Po0.05 in at least two adjacent chromosomal loci 
were considered and the reported individual P- 
value was set to equal the highest (least significant) 
one.
Correlation-based tree modeling was applied to 
the data in order to create a correlation matrix, 
describing the relationship between all possible 
pair-wise comparisons between individual cases. 
Case similarities were calculated using the Pearson 
correlation adjusted to account for values centered 
to zero. The values of the matrix were used to 
generate a tree structure or dendrogram, employing 
an agglomerative algorithm using unweighted pair-
Modern Pathology (2006) 19, 1068 –1082
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Figure 1 Summary of gains and losses of DNA sequence copy number in 32 primary non-uterine leiomyosarcoma samples analyzed by 
CGH. Losses are shown on the left side of the chromosome and gains on the right. Each vertical line represents a genetic alteration seen in 
one sample. High-level amplifications of small chromosomal regions are shown as thick lines.
group average linkage amalgamation rules. Branch 
lengths in the resulting tree reflect the degree of 
correlation, while joining nodes depict the pairs of 
cases with the highest correlation. Cases with 
similar patterns of aberrations will achieve a high 
degree of correlation and thus appear close in the 
dendrogram, whereas cases with little in common 
with respect to aberration pattern will end up far 
apart. The same algorithm was employed to cluster 
the aberrations with respect to case patterns. The 
resulting tree-models representing correlations 
between the cases (vertical orientation) and corre­
lations between the aberrations (horizontal orienta­
tion) were depicted in a 2-dimensional graph that 
displayed also the pattern (as absence or presence) 
of any particular aberration and case. Associations 
between the branches at any level of the tree and the 
clinical parameters mentioned above, that is, tumor 
subtype, localization, histologic grade and metasta­
sis, were assessed by overlaying the respective 
information on the 2-D dendrogram and analyzing 
their relation to the vertical branching pattern. The 
statistical evaluation was performed by comparing 
the distribution of cases representing the different 
levels of a given clinical parameter to the distribu­
tion observed in all 51 cases. The F or binomial 
distributions were used in the calculations accord­
ing to the number of categories in the tested 
parameter. Aberrations that contributed most sig­
nificantly to the identified branching patterns were 
calculated in a similar fashion, using Fisher's exact 
test to compare the observed and expected distribu­
tions. Lists ranking the relative importance of 
aberrations for a given cluster in the tree were 
obtained by taking the negative logarithm of the P- 
values from Fisher's exact test.
Results
Overview of DNA Sequence Copy Number Changes
Revealed by CGH
Of the 51 leiomyosarcoma samples studied, 48 
(94%) had changes with a mean value of 11. 
0270.96 aberrations per sample (range, 1–25). Three
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Figure 2 Summary of gains and losses of DNA sequence copy number in 19 primary uterine leiomyosarcoma samples analyzed by CGH. 
Losses are shown on the left side of the chromosome and gains on the right. Each vertical line represents a genetic alteration seen in one 
sample. High-level amplifications of small chromosomal regions are shown as thick lines.
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samples (6%) did not show any aberrations. The 
absence of detectable changes could be attributable 
to non-neoplastic DNA extracts, intratumor hetero­
geneity, or the underlying shortcomings in the 
resolution of CGH.
Gains of DNA copy number changes were as 
frequent as losses (gains:losses ¼ 1.0:1.1) with a 
mean value of 4.8870.51 (range, 0–15) and 
5.4070.55 (range, 0–14) aberrations per sample, 
respectively. High-level amplifications of small 
chromosomal regions were found in 23 out of the 
51 (45%) tumors analyzed with a mean value of 
0.7570.15 aberrations per sample (range, 0–5).
Of the 32 non-uterine tumors (nos 1–32), 30 (94%) 
had changes with a mean value of 10.5371.03 
aberrations per sample (range, 2–22). Two low-grade 
tumors (6%) did not show any aberrations (nos 1 
and 4). Gains were as frequent as losses 
(gains:losses ¼ 1.0:1.1) with a mean value of 
4.6770.51 (range, 0–11) and 5.1070.63 (range, 0– 
13) aberrations per sample, respectively. High-level 
amplifications were found in 16 out of the 32 tumors 
analyzed with a mean value of 0.7770.17 aberra­
tions per sample (range, 0–5).
Among the 30 non-uterine tumors with DNA copy 
number changes, gains were frequent in chromo­
somes 1 (40%), 5 (37%), 8 (27%), 9 (27%), 15 (27%), 
17 (40%), 19 (33%), 20 (30%), and 22 (33%). High- 
level amplifications were found in 16 out of the 30 
(53%) abnormal tumors analyzed, with the highest 
frequency in chromosome 17 (33%). Losses fre­
quently affected chromosomes 2 (37%), 6 (40%), 8 
(30%), 10 (50%), 13 (70%), 16 (40%), and X (37%). 
Figure 1 summarizes all chromosomal regions 
with increased or decreased DNA sequence copy 
number changes in the non-uterine leiomyosarcoma 
samples.
Of the 19 uterine tumors (nos 33–51), 18 (95%) 
had changes with a mean value of 11.8371.93 
aberrations per sample (range, 1–25) while only one 
(5%) of the low-grade tumors (no 33) did not reveal 
any DNA copy number changes. Gains were as 
frequent as losses (gains:losses ¼ 1.0:1.1) with a 
mean value of 5.2271.10 (range, 0–15) and
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5.8971.03 (range, 0–14) aberrations per sample, 
respectively. High-level amplifications were found 
in 7 out of the 19 tumors analyzed with a mean value 
of 0.7270.30 aberrations per sample (range, 0–5).
Among the 18 uterine tumors with DNA copy 
number changes, gains were frequent in chromo­
somes 1 (56%), 3 (28%), 5 (28%), 8 (44%), 12 (28%), 
16 (28%), 17 (33%), and 20 (28%). High-level 
amplifications were found in seven out of the 18 
(39%) abnormal tumors analyzed, with the highest 
frequency in chromosome 1 (17%). Losses fre­
quently affected chromosomes 2 (50%), 4 (28%), 6 
(39%), 7 (33%), 11 (44%), 13 (44%), 14 (39%), and 
16 (50%). Figure 2 summarizes all chromosomal 
regions with increased or decreased DNA sequence 
copy number changes in the uterine leiomyosar­
coma samples. Table 2 shows the copy number 
karyotypes of the 51 primary leiomyosarcoma 
samples analyzed by CGH.
Minimal Common Regions of DNA Sequence Copy 
Number Changes
The minimal common regions of DNA copy number 
changes in the whole series of 51 leiomyosarcomas 
were determined. The minimal common regions 
of recurrent gains were 1q11–q31 (24–33%), 
5cen-p15.3 (22–25%), 8q21.3–q24.3 (22–25%), 15q 
(14–20%), 17cen.p12 (22–24%), 17cen.q21 (24%), 
19p (22–24%), 20q (25%), and 22q (24–27%), and 
the most frequent high-level amplifications were 
1q21 (8%), 5p13.p15.2 (8%), and 17p (14–18%). 
The regions of recurrent losses were 2q32.1–q37 
(22–29%), 6cen.p25 (22–24%), 6cen.q22 (24–25%), 
9p21.p24 (22%), 10cen.p15 (22–24%), 10cen.q26 
(27–35%), 13q (31–57%), 14q (8–18%), 16q (35– 
41%), and Xq21-q28 (27–29%).
The minimal common regions in all leiomyo­
sarcoma samples are presented at our web 
site (supplementary data www.helsinki.fi/cmg/cgh_ 
data).
Results from Statistical Analyses
To evaluate whether specific aberration patterns 
could be associated with clinically relevant para­
meters, such as tumor subtype (uterine vs non­
uterine), localization (cutaneous, subcutaneous, 
deep-seated, or uterine), histologic grade (low vs 
high), and metastatic recurrence, the CGH data was 
studied in greater detail using both univariate and 
higher order statistical modeling. In order to focus 
the analysis on the most prominent and representa­
tive aberrations, simultaneously achieving the aim 
of minimizing the occurrence of noise in the data, 
inclusion cut-offs were defined. Gains and losses 
were included in the analysis when at least 10.0% of 
the cases shared the aberration, whereas the con­
siderably less frequent high-level amplifications 
were included even when single cases were affected. 
Consequently, the number of aberrations came down 
from 387 loci to 173 aberrations, the minimal 
common regions in all 51 tumors (supplementary 
data at www.helsinki.fi/cmg/cgh_data).
The significance of individual aberrations was 
explored in greater detail by ranking the aberrations 
with respect to their power to discriminate between 
the categories of clinical parameters, based on the 
calculation of a ‘prediction strength' score,38 fol­
lowed by univariate w2 testing of the top ranking 
aberrations. No statistically significant results were 
found for tumor subtype, localization or grade, but 
for metastatic status significant differences were 
found in the cases with and without losses at 6cen- 
p25 and 2q32.1–q37, or gains at 8q24.1-q24.3, with 
adjusted P-values of 0.017, 0.035, and 0.035, 
respectively. Further analysis, which took the time 
variable into account, used the log-rank test to 
evaluate the differences in metastasis-free survival 
rates with regard to aberration status, confirmed the 
importance of these aberrations and resulted in 
adjusted P-values of 0.012, 0.009, and 0.009 (order 
as above). The cases with these aberrations demon­
strated a decreased survival rate, with the notable 
exception of cases with losses at 6p, for which the 
opposite was found, suggesting that losses at 6p 
confer a protective effect resulting in significantly 
higher metastasis-free survival rates as compared to 
cases without them (Figure 3).
Higher order modeling of the data, both with 
respect to correlations between cases and correla­
tions between aberrations, are summarized in a 
2-dimensional dendrogram (Figure 4a). Vertical 
branching pattern did not identify any clear-cut 
division into clusters that would exclusively repre­
sent individual categories according to any of the 
tested clinical parameters, that is, tumor subtype, 
localization, histologic grade, and metastasis. How­
ever, closer scrutiny of the branching structure by 
overlaying information of the leiomyosarcoma sub­
type (uterine vs non-uterine) revealed two branches, 
a few levels down from the top of the dendrogram, 
that clearly segregated the two subtypes. The larger 
branch, denoted cluster A (Figure 4a, b), consisted of 
11 cases, of which 10 (91%) were non-uterine, 
whereas the smaller branch, cluster B (Figure 4a, c), 
included six cases, of which five (83%) were 
uterine. Statistically both of these proportions 
were significantly different from the distribution 
expected to be observed by chance, P ¼ 0.044 and 
0.030 for clusters A and B, respectively. Further 
characterization of the clusters disclosed some 
interesting features regarding the cases in cluster 
A. Compared to the overall distribution of cases 
with regard to tumor localization (cutaneous, sub­
cutaneous, deep-seated, or uterine), cluster A had a 
significantly higher proportion of subcutaneous 
tumors and a significantly lower proportion of 
deep-seated tumors (P ¼ 0.024). A trend indicating 
a lower proportion of metastatic recurrence among 
these cases was also observed (P ¼ 0.098), which
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Table 2 DNA sequence copy number changes in the 51 primary leiomyosarcoma samples analyzed by CGH
Sample DNA sequence copy number changes, CGH results 
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
rev ish normal
rev ish enh(5p) dim(6, 10, 16, 17)
rev ish enh(6q, 17cen.q21, 19pter.q13.2) dim(6p, 13cen.q21) amp(17p)
rev ish normal
rev ish enh(1, 12q, 15q15.qter, 16cen.p11.2) dim(2q35.qter, 6p21.3pter, 7q33.qter, 8pter.q22, 10q, 12p, 13, 16q, 18, 21, 22, Xq) amp(17p)
rev ish enh(1p13.q21, 3p14.pter, 16p, 19, 22) dim(1q31.qter, 8q13.qter, 9p21.pter, 10q21.qter, 13q12.q31, 16q, Xq21.qter) amp(17p)
rev ish enh(2p12.p14, 14) dim(2p21.pter, 10, 13, 16)
rev ish dim(1p21.p31, 6, 9p, 13, 14q11.2.q24, Xq22.qter)
rev ish dim(13, 16)
rev ish enh(1q21.q24, 4p16, 8p, 15, 17, 19, 20q, 22) dim(2q22.q35, 4q, 6q11.q23, 9p13.pter, 13q13.q32) amp(17p13.pter)
rev ish enh(3q24.qter, 6) dim(4q22.q28, 8, 15)
rev ish enh(9q11.q21, 14, 15, 17cen.q21) dim(6p, 7, 10q21.qter, 13, 16q, X) amp(17p)
rev ish enh(1q12.q31, 5pter.q14, 5q34.qter, 8q11.q13, 8q23.qter, 12q, 16p, 19, 20q, Xpter.q13) dim(1q41.qter, 4q, 8p12.pter, 8q21.3.q22, 11q23.qter, 13, 16q, Xq21.qter) 
amp(1q21, 5p13.pter, 12q13.q21, 12q23.qter)
rev ish enh(3q, 9p, 15, 17, 22) dim(6p, 8p, 10, 12p, 12cen.q15, 13q14.qter, 16)
rev ish enh(5p, 9q, 17p, 22p, 22cen.q12) dim(2q22.qter, 12p12.pter, 13q12.q31, 17q21.qter, 21q, 22q13.qter)
rev ish enh(2q11.2.q14.3, 5p, 9p, 9cen.q22, 15, 17, 18, 19p, 20, 21, 22) dim(2q24.q32.3, 8p21.pter, 10, 11, 13q14.qter, 16, Xq21.qter)
rev ish enh(1q21.q22, 8q, 9q, 17p, 20q, Xp) dim(1q24.q32, 2q33.qter, 6q, 8p, 9p, 10q, 11p, 11q14.qter, 13q14.qter, 18, Xq) amp(17p12, Xp21.pter)
rev ish enh(1pter.q31, 6p, 9, 10p12.pter, 17, 20, Xp) dim(2q22.qter, 3p, 4p, 12p, Xq21.qter) amp(1q21.q24, 5p, 17p12.pter)
rev ish enh(5, 20, 22)
rev ish enh(1q21.q23, 3q26.3.qter, 5p, 16p, 19, 20q) dim(1q32.qter, 2p12.pter, 2q32.3.qter, 5q32.qter, 6q, 8p, 10, 11, 12, 13q12.q31, 17q, 22, Xpter.q25) amp(20p)
rev ish enh(11q11.q21, 14q23.qter, 19, Xp, Xq22.q27) dim(2p15.pter, 2q33.qter, 4q, 6q, 10p13.pter, 10q, 13q11.q21) amp(17p)
rev ish enh(7q, 10p, 15pter.q23, 19p, Xpter.q21, Xq27.qter) dim(1p36.1.pter, 6p, 7p, 8p21.pter, 10q, 13q14.qter, 16q13.q21, 19q, 20p11.2.pter) amp(17p)
rev ish enh(1pter.q31, 2p22.p23, 5cen.p15.2, 7cen.p21) amp(Xcen.p22.1)
rev ish enh(1q12.q23, 8) dim(2, 4q, 10, 13q14.q22)
rev ish enh(5p14.qter, 7p, 8, 9pter.q31, 14pter.q13, 17cen.p12, 22) dim(5p14.pter, 10, 11q14.qter, 13, 14q22.qter, 16q, Xq13.qter)
rev ish enh(1p31.pter, 6p, 8q23.qter, 15q22.qter, 16p, 17, 19, 20q, 22) dim(4q, 5q11.q14, 6q, 9p, 9q11.q21, 12q11.q23, Xq) amp(22q11.2)
rev ish enh(2, 3q, 7p, 8q)
rev ish enh(5, 8q21.3.qter, 20, 22, X) amp(5p13.pter, 8q24.2.qter)
rev ish enh(1q11.q25, 14q22.qter) dim(2p21.pter, 2q32.qter, 9p, 10, 11q21.qter, 13q13.q22)
rev ish enh(11p) dim(10p, 16q)
rev ish enh(5, 7, 9, 14, 16p, 17q, 19, 22) dim(13q14.q31) amp(17q24.qter)
rev ish enh(1p31.q23, 5q21.qter, 15, 17q) dim(9p, 13q) amp(11q14.q22)
rev ish normal
rev ish enh(1p31.q31, 2p14.q24, 3q26.3.qter, 4p, 6p, 7q11.2.q22, 8cen.q22, 11q14.q23, 15q15.qter, 16p, 17q, 18pter.q12, 20p12.qter, 22) 
dim(4q24.qter, 6q16.qter, 7q32.qter, 9, 11p, 12q22.qter, 13q21.qter, 14, 16q13.q23, 19, Xq13.qter)
rev ish enh(12) dim(1p34.3.pter, 2p15.pter, 6pter.q24, 11q14.q23, 14q21.qter, 15pter.q24, 16q, 22)
rev ish dim(16q)
rev ish enh(1q21.q31, 8q21.1.qter, 17p, 19q, 20q, Xp) dim(1q32.qter, 2p22.pter, 2q, 4p, 6cen.q21, 7q, 10q22.qter, 12p, 13cen.q31)
rev ish enh(1cen.q31) dim(16)
rev ish enh(1cen.q32)
rev ish enh(1q, 8q, 16p, 17, 20q) dim(1p, 3q22.qter, 6pter.q15, 14, 15, 18) amp(8q24.1.qter)
rev ish enh(5p13.pter, 9q33.qter, 17p) dim(Xq13.qter)
rev ish enh(1p22.qter, 3p22.pter, 8q21.3.qter, 17) dim(2p, 4cen.q24, 8p, 11q14.q22, 13q14.q33, 14q13.qter, 16q, 21, Xq) amp(1q12.q32)
rev ish enh(12q15.qter, 17p12.pter, 18q21.qter, 22cen.q12) dim(2q21.qter, 5p, 7cen.q32, 9p, 11q14.qter, 13, 14p, 14cen.q24, 16q, 18p, 19p, 21, 22q13.qter)
rev ish enh(8q) dim(14q24.qter, 16q13.qter, 21)
rev ish enh(1cen.q32, 14) dim(2q32.1.qter, 11p12.p15) amp(1q25.q31)
rev ish enh(1q, 11q, 12q13.q24.1) dim(2p22.pter, 6p21.3.q22, 13, 17)
rev ish enh(2q11.q23, 5p, 7p, 10p, 11q, 12p, 12cen.q15, 14p, 14cen.q24, 15q21.qter, 18q, 20, 22) dim(2q24.qter, 4q, 5q14.qter, 6, 7q, 8q13.qter, 9p13.pter, 10q) 
amp(15q22.qter, 20q)
rev ish enh(8, 9q32.qter, 15q13.qter, 16p, 19p, 22) dim(2q33.qter, 3p, 6p, 6cen.q22, 9p, 10p, 10q23.q25, 11p, 13p, 13cen.q21, 16q, 17, 18, 21) amp(19p13.2.pter)
rev ish enh(1p35.q32, 3, 5, 7, 11cen.p13, 13q31.qter) dim(11q, 13cen.q21, 16) amp(1p31.q25) 
rev ish enh(3, 5p, 6, 8q, 9, 16p, 18, 19, 20) dim(2, 4, 7, 10, 11q14.qter, 13, 14cen.q31, 17, X)
rev ish enh(1p31.p33, 1cen.q32, 2pter.q14.1, 3p, 4pter.q13, 5pter.q14, 6cen.p21.3, 6q, 7p, 7cen.q22, 8p, 12p, 15, 16q21.qter, Xp) dim(1q41.qter, 5q21.qter, 7q34.qter, 18p) 
amp(4p, 5p15.2.q13, 15q21.qter, 17p, Xp21.pter)
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Figure 3 Kaplan–Meier curves show metastasis-free survival for 
cases with (a) loss at 2q32.3, (b) loss at 6p21.3, and (c) gain at 
8q24.1 compared to cases without the aberration. Solid curves 
represent cases with the specific aberration and dashed curves 
cases without the aberration.
was additionally substantiated when the time vari­
able was included in the log-rank test for difference 
in the Kaplan–Meier curves (P ¼ 0.088). Cases in 
cluster B did not exhibit similar significant differ­
ences when compared to the whole study group 
(Figure 4d). In an effort to determine the aberrations 
underlying the observed segregation into the two 
clusters, the ability of each aberration to predict 
cluster membership was evaluated using Fisher's 
exact test. A list ranking the aberrations with respect 
to prediction strength was obtained by taking the 
negative logarithm of the P-values from Fisher's 
exact test. Among the highest ranked aberrations 
were losses in 13q14-q34, 16q11.1-q24, and 10q21- 
q26 as well as gains in 1q11-q24 (Table 3). All the 
above losses were specific to cluster A, whereas 
gains in 1q were specific to cluster B.
When the branching pattern was analyzed for the 
horizontal tree-model based on correlations between 
aberrations, it was apparent that correlation strength 
associated with physical closeness. With only a few 
exceptions, likely due to small number of occur­
rences limiting the accuracy of the calculations, 
clusters of aberrations consisted of events affecting
Table 3 CGH aberrations ranked according to their ability to 
segregate clusters A and B identified by 2-dimensional tree­
modeling
Prediction strength was calculated using the negative logarithm of the 
P-values from Fisher's exact test (only top ranking aberrations shown).
Aberration Prediction 
strength
Cluster A 
No. of cases (%)
Cluster B 
No. of cases (%)
dim(13q21) 9.424 11 (100) 0 (0)
dim(13q14) 9.424 11 (100) 0 (0)
dim(13q22) 9.424 11 (100) 0 (0)
dim(13q31) 9.424 11 (100) 0 (0)
dim(13q33) 7.478 10 (91) 0 (0)
dim(13q32) 7.478 10 (91) 0 (0)
dim(16q13.q21) 6.939 11 (100) 1 (17)
enh(1q22) 6.091 2 (18) 6 (100)
enh(1q24) 6.091 2 (18) 6 (100)
enh(1q23) 6.091 2 (18) 6 (100)
enh(1q21) 6.091 2 (18) 6 (100)
dim(13q34) 6.091 9 (82) 0 (0)
dim(16q24) 5.219 10 (91) 1 (17)
dim(16cen.q12.2) 5.219 10 (91) 1 (17)
dim(16q22.q23) 5.219 10 (91) 1 (17)
enh(1q11) 4.993 3 (27) 6 (100)
dim(10q23.q25) 4.993 8 (73) 0 (0)
dim(10q22) 4.993 8 (73) 0 (0)
dim(10q26) 4.993 8 (73) 0 (0)
enh(1q12) 4.993 3 (27) 6 (100)
dim(10q21) 4.993 8 (73) 0 (0)
Figure 4 (a) Two-dimensional correlation-based tree modeling of 51 leiomyosarcoma cases and 173 chromosomal aberrations. Each 
column represents a case and each row an aberration. Red in the matrix indicates presence and gray absence of a particular aberration. 
The dendrogram at the top shows the degree of similarity between the cases, and the dendrogram on the left side shows similarities 
between aberrations. The clusters that segregate non-uterine cases (cluster A) and uterine cases (cluster B), and the aberrations that most 
significantly contribute to the segregation pattern are highlighted. (b and c) Sub-dendrograms of clusters A and B in panels b and c, 
respectively, show non-uterine cases in red and uterine in green. (d) Kaplan–Meier curve shows differences in metastasis-free survival 
between cluster A (P ¼ 0.088) (red curve), cluster B (green curve) and the whole study group (black curve).
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adjacent loci on the same chromosome segment. 
There were thus no indications of physically 
unrelated aberrations co-occurring in the study 
group.
Discussion
Our study reports a CGH analysis performed on a 
large series of primary leiomyosarcomas comprising 
19 uterine tumors and 32 non-uterine tumors of 
various external soft tissue sites. The aim was to 
evaluate whether true biological differences exist 
between uterine and non-uterine leiomyosarcomas. 
We obtained a genome-wide pattern of chromosomal 
gains, losses, and high-level amplifications of small 
chromosomal areas, and evaluated their possible 
prognostic and/or diagnostic significance using 
high-order statistical modeling. Two clusters clearly 
segregated uterine samples from non-uterine 
samples and the non-uterine cluster showed a trend 
of increased metastasis-free survival time. Further­
more, we identified some DNA copy number 
changes that are associated with higher metastatic 
potential.
Similarities and Differences in DNA Sequence Copy 
Number Changes of Uterine and Non-Uterine 
Leiomyosarcoma
The CGH analysis showed genomic imbalances in 
48 (94%) of the 51 leiomyosarcomas studied. We 
found some general similarities between uterine and 
non-uterine leiomyosarcomas, such as gains of DNA 
copy number changes were nearly as frequent as 
losses in both uterine and non-uterine samples. In 
accordance with previous CGH studies, we found 
highly complex karyotypic changes in both sub­
types. None of the most frequent gains or losses in 
either tumor group were unique and no specific 
aberration was restricted to any subtype of leiomyo­
sarcoma. However, we found some typical and 
nearly consistent DNA copy number changes, 
including high frequency of losses in 10q (35% of 
all 51 tumors), 13q (57%) and 16q (41%), gains in 1q 
(41%), and gains and high-level amplifications in 
17p (39%); aberrations that have been reported in 
previous CGH studies of leiomyosarcoma.21,23–28 The 
high frequency of chromosome imbalances suggests 
the presence of pathogenetically relevant oncogenes 
or tumor suppressor genes within these chromo­
some regions.
The purpose of our study was to evaluate possible 
differences between chromosomal aberrations in 
uterine and non-uterine leiomyosarcoma. To our 
knowledge, no previous study has focused on this 
issue or analyzed CGH results of leiomyosarcoma 
using correlation-based tree modeling, which was 
possible on this a large series of cases with complex 
chromosome imbalances. However, similar type of 
unsupervised clustering analysis, which is com­
monly used for the analysis of gene expression 
arrays, has also been applied to analysis of CGH data 
of sarcoma.39 Although no pathognomonic aberra­
tions for non-uterine or uterine leiomyosarcoma, or 
clear-cut division into clusters exclusively repre­
senting any of the clinical parameters (subtype, 
localization, grade, and metastasis) tested were 
found, we revealed two clusters that segregated 
significantly a group of uterine tumors with 
gains at 1q11–q24 and a group of non-uterine 
tumors with losses at 13q14–q34, 16q11.1–q24, 
and 10q21–q26.
In the larger cluster, 10 of 11 tumors were non­
uterine, and in the smaller cluster 5 of six tumors 
were uterine. The non-uterine cluster showed a 
trend indicating decreased metastatic recurrence, 
and the proportion of subcutaneous tumors was 
significantly higher than expected. As statistical 
testing of differences in proportion of low-grade or 
small tumors in the non-uterine cluster with favor­
able survival rates did not show significance, these 
parameters did not explain the finding (data not 
shown). The highest ranked aberrations in the non­
uterine cluster, that is, losses in 13q, 16q, and 10q, 
have previously been connected and associated with 
decreased metastatic rate. Our results are in accord 
with the cytogenetic study by the CHAMP Study 
Group,18 which showed that losses of 10q and 13q 
segments were more frequent among patients with­
out metastases. Interestingly, El-Rifai et al21 found 
frequent losses in 10q and 13q, and 71% of cases 
with loss in 13q had losses in 10q, suggesting a 
cumulative effect of deletions of several tumor 
suppressor genes in leiomyosarcoma. Furthermore, 
Hu et al27 studied exclusively uterine leiomyo­
sarcoma and found that loss of 13q (without loss 
of 10q) was associated with longer survival time. 
They suggested that loss of tumor suppressor gene 
in 13q may be an early event in the development 
of leiomyosarcoma, and activation or inactivation 
of other oncogenes and tumor suppressor genes may 
be responsible for tumor progression.
In the present study, deletions of chromosome 13 
involved several minimal overlapping regions of 
13q. The region at 13q14, which contains the tumor 
suppressor gene RB, showed losses in 55% of 
the cases. Alterations of RB are frequent in a wide 
range of malignancies, in leiomyosarcoma as well 
as in other soft-tissue sarcomas.40,41 Analyses of the 
genes and proteins in the Rb-cyclin D pathway 
have revealed frequent abnormalities in leiomyo- 
sarcoma.23,42,43
Standard cytogenetic methods have rarely re­
vealed rearrangements of 10q in leiomyosarcoma.16 
By CGH, we observed recurrent losses at 10q 
with the highest rate at 35% in the most frequent 
minimal common region of 10q23.q25. This finding 
is consistent with previous results reported 
in leiomyosarcoma and a wide range of other 
malignancies.21,23,25,27,41,44,45 The tumor suppressor 
gene PTEN is mapped to 10q23.45 This chromosomal 
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region is commensurate with the frequent loss of 
heterozygosity of chromosome 10 demonstrated in 
uterine leiomyosarcoma but not in leiomyomas.46 
Moreover, MXI1, a negative regulator of the MYC 
oncoprotein having a tumor suppressor function is 
mapped to 10q24–25.41,47
About 41% of our cases showed losses in 16q. 
This observation is in agreement with the find­
ings that Hu et al27 reported in uterine leiomyo­
sarcoma. Several putative tumor suppressor genes 
are assigned to this region. Among them are 
RB2/p130 (16q12.2), CDH1 (16q22.1), and CDH13 
(16q24.2.q24.3).41,48
Gains in chromosome 1q were specific for the 
small uterine cluster. Furthermore, 33% of our cases 
with gains in chromosome 1q shared a minimal 
common overlapping region of 1q21. Also high-level 
amplification of this minimal common region was 
observed. Skubitz et al49 demonstrated that the 
expression of cellular retinoic acid-binding protein 
gene type II (CRABP2), located at 1q21.3, is five- to 
10-fold in leiomyosarcoma as compared to normal 
myometrium. Increased sequence copy number at 
1q21.q23 has been detected frequently in several 
malignancies (see Knuutila et al50 and references 
therein), but especially in sarcomas, including 
leiomyosarcoma, liposarcoma, osteosarcoma, chon­
drosarcoma, and malignant fibrous histiocyto- 
ma.21,24,26,27,34,44,51–56 This region harbors several 
genes of potential significance.56–58
Our study showed gains and high-level amplifica­
tions in 17p in approximately 40% of the cases. A 
difference in the frequency of high-level amplifica­
tions affecting 17p was observed between non­
uterine (28%) and uterine tumors (5.3%). Thus our 
data support previous CGH analyses, which have 
reported high-level amplifications in 17p in 20–30% 
of extra-uterine cases and, sporadically, in uterine 
cases.21,23,24,26,27 One of the best known tumor 
suppressor genes, TP53, is located at 17p13, and 
p53 and p53 protein overexpression has been 
described in leiomyosarcoma.42,59–62 Gains as well 
as high-level amplifications at 17p11.p12 seem to be 
frequently involved in other sarcomas, including 
osteosarcoma, chondrosarcoma, and malignant 
fibrous histiocytoma.21,23,27,34,44,51–53,63,64 This suggests 
that different sarcoma entities most probably share a 
common pathogenic pathway.
In the present study, we found high-level ampli­
fications in 1q, 5p, and Xp, which have been 
sporadically found in previous leiomyosarcoma 
studies.20–23,25 Recurrent high-level amplifications 
on chromosome arms 5p, 17p, and Xp have also 
been observed in osteosarcoma, malignant fibrous 
histiocytoma, and liposarcoma.51,53,65,66 Interest­
ingly, the frequently amplified regions we observed 
on chromosome arms 5p, 17p, and Xp all harbor 
genes involved in the ubiquitin-mediated protein 
degradation pathway.67 Otan˜ o-Joos et al23 have 
described a similar pattern of chromosomal involve­
ment.
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Comparison of our findings to clinicopathological 
factors showed no significant correlation between 
any single CGH aberration and tumor subtype 
(uterine vs non-uterine), localization (cutaneous, 
subcutaneous, deep-seated, or uterine), or grade 
(low vs high). However, statistical analysis of 
metastasis-free survival revealed a significantly 
shorter survival time for cases with losses at 
2q32.1–q37 or gains at 8q24.1–24.3. In contrast, 
cases with losses at 6cen-p25 showed significantly 
longer metastasis-free survival time. We further 
analyzed whether cases with and without the 
aberration in question differed with respect to 
proportion of cases with respective tumor localiza­
tions or grade. We revealed a statistically significant 
increase in the proportion of high-grade tumors 
among cases with gain at 8q24.1 (P¼ 0.020) and a 
similar strong trend for losses at 2q33–q34 and 
2q36–q37 (P¼ 0.052) (data not shown). Non-signifi- 
cant values were observed for the remainder of 
aberrations and with regard to tumor localization.
Losses at 2q32.1–q37 and 6cen-p25 have pre­
viously not been associated with metastasis in 
leiomyosarcoma. However, losses of regions at 2q 
have been detected in osteosarcoma, with minimal 
common region 2q34-qter,51 and a study of Ewing 
sarcoma and related tumors cases with gains at 
6p21.1-pter showed a statistically significant de­
crease in metastasis-free and overall survival.68 The 
number of previous studies on leiomyosarcoma is 
small and only few associations between DNA copy 
number changes in leiomyosarcoma and prognosis 
have been observed.18,21,27,28
In the present study, we found that gains at 
8q24.1–q24.3 were significantly associated with 
metastatic potential. The 8q24.1 region contains 
the proto-oncogene c-MYC, which is known to be 
amplified in several tumors. Frequent gains and 
high-level amplifications in 8q, with the minimal 
common overlapping region of 8q24.1, have been 
described in large (5–20 cm) and very large (420 cm) 
leiomyosarcomas, but these findings were not tested 
statistically for metastasis.21 In synovial sarcoma, 
gains of 8q were significantly overrepresented in 
large tumors.69 Furthermore, in Ewing sarcoma and 
related tumors, copy number increases of chromo­
some 8 were associated with trends towards worse 
metastasis-free and overall survival,68 in osteosarcoma 
with a statistically significant poor metastasis­
free survival, and in chondrosarcoma with shorter 
overall survival.65 Our findings suggest that copy 
number increase at 8q24.1–q24.3 might reflect 
the aggressiveness and dissemination capacity of 
the tumor.
In conclusion, we found some typical and nearly 
consistent DNA copy number changes, for example, 
losses in 10q, 13q, and 16q, gains in 1q, and gains 
and high-level amplifications in 17p. We revealed
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two clusters that significantly segregated uterine 
and non-uterine leiomyosarcomas and found that 
the non-uterine cluster showed a trend towards 
increased metastasis-free survival. Further explora­
tive analyses identified aberrations associated with 
shorter metastasis-free survival, that is losses at 
2q32.1–q37 and gains at 8q24.1–q24.3. In contrast, 
the cases with losses at 6cen-p25 showed longer 
metastasis-free survival. The true prognostic impact 
of these aberrations should be verified on an 
independent sample set.
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